Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up von Fohlin, Helena, Nordenskjöld, Anna, Rosell, Johan, Fernö, Mårten, Fornander, Tommy, Rydén, Lisa, Skoog, Lambert, Nordenskjöld, Bo, Stål, Olle

Volltext

Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up von Lundgren, Christine, Bendahl, Pär-Ola, Ekholm, Maria, Fernö, Mårten, Forsare, Carina, Krüger, Ute, Nordenskjöld, Bo, Stål, Olle, Rydén, Lisa

Volltext

PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer von Perez-Tenorio, Gizeh, Alkhori, Liza, Olsson, Birgit, Waltersson, Marie Ahnstroem, Nordenskjoeld, Bo, Rutqvist, Lars Erik, Skoog, Lambert, Staal, Olle

Volltext

Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial von Lundgren, Christine, Tutzauer, Julia, Church, Sarah E, Stål, Olle, Ekholm, Maria, Forsare, Carina, Nordenskjöld, Bo, Fernö, Mårten, Bendahl, Pär-Ola, Rydén, Lisa

Volltext

Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy von Nordenskjöld, Anna, Fohlin, Helena, Rosell, Johan, Bengtsson, Nils-Olof, Fornander, Tommy, Hatschek, Thomas, Lindman, Henrik, Malmström, Per, Rydén, Lisa, Wallgren, Arne, Stål, Olle, Nordenskjöld, Bo

Volltext

High Progesterone Receptor Expression Correlates to the Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer Patients von Stendahl, M., Ryden, L., Nordenskjöld, Bo, Jonsson, P.E., Landberg, G., Jirstrom, K.

Volltext

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit von Bostner, Josefine, Karlsson, Elin, Pandiyan, Muneeswaran J., Westman, Hanna, Skoog, Lambert, Fornander, Tommy, Nordenskjöld, Bo, Stål, Olle

Volltext

Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer von Hilborn, Erik, Gacic, Jelena, Fornander, Tommy, Nordenskjöld, Bo, Stål, Olle, Jansson, Agneta

Volltext

Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen von Khoshnoud, Mahmoud R, Löfdahl, Britta, Fohlin, Helena, Fornander, Tommy, Stål, Olle, Skoog, Lambert, Bergh, Jonas, Nordenskjöld, Bo

Volltext

Hormone receptor mRNA and protein levels as predictors of premenopausal tamoxifen benefit von Engström, Terese, Ekholm, Maria, Fernö, Mårten, Lundgren, Christine, Nordenskjöld, Bo, Stål, Olle, Bendahl, Pär-Ola, Tutzauer, Julia, Rydén, Lisa

Volltext

PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients von Lundgren, Christine, Bendahl, Pär-Ola, Church, Sarah E., Ekholm, Maria, Fernö, Mårten, Forsare, Carina, Krüger, Ute, Nordenskjöld, Bo, Stål, Olle, Rydén, Lisa

Volltext

GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer von Sandström, Josefine, Bomanson, Jens, Pérez-Tenorio, Gizeh, Jönsson, Carolin, Nordenskjöld, Bo, Fornander, Tommy, Lindström, Linda S., Stål, Olle

Volltext

PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer von Karlsson, Elin, Veenstra, Cynthia, Gårsjö, Jon, Nordenskjöld, Bo, Fornander, Tommy, Stål, Olle

Volltext

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients von Wegman, Pia, Vainikka, Linda, Stål, Olle, Nordenskjöld, Bo, Skoog, Lambert, Rutqvist, Lars-Erik, Wingren, Sten

Volltext

The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype von Veenstra, Cynthia, Karlsson, Elin, Mirwani, Sanam Mirwani, Nordenskjöld, Bo, Fornander, Tommy, Pérez-Tenorio, Gizeh, Stål, Olle

Volltext

Ratio of 17HSD1 to 17HSD2 Protein Expression Predicts the Outcome of Tamoxifen Treatment in Postmenopausal Breast Cancer Patients von JANSSON, Agneta, DELANDER, Lovisa, GUNNARSSON, Cecilia, FORNANDER, Tommy, SKOOG, Lambert, NORDENSKJÖLD, Bo, STAL, Olle

Volltext

Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer von Bostner, Josefine, Skoog, Lambert, Fornander, Tommy, Nordenskjöld, Bo, Stål, Olle

Volltext

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer von Bostner, Josefine, Alayev, Anya, Berman, Adi Y., Fornander, Tommy, Nordenskjöld, Bo, Holz, Marina K., Stål, Olle

Volltext

Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer von Karlsson, Elin, Veenstra, Cynthia, Emin, Shad, Dutta, Chhanda, Pérez-Tenorio, Gizeh, Nordenskjöld, Bo, Fornander, Tommy, Stål, Olle

Volltext

17β-Hydroxysteroid dehydrogenase type 14 is a predictive marker for tamoxifen response in oestrogen receptor positive breast cancer von Sivik, Tove, Gunnarsson, Cecilia, Fornander, Tommy, Nordenskjöld, Bo, Skoog, Lambert, Stål, Olle, Jansson, Agneta

Volltext